MRI-guided transurethral ultrasound prostate ablation: midterm outcomes of a phase I clinical trial

Mathieu Burtnyk,Joseph Chin,Sascha Pahernik,Ionel Valentin Popeneciu,Matthias Roethke,James Relle,Michele Billia,Heinz-Peter Schlemmer,Jason Hafron

doi:10.1186/2050-5736-3-s1-o60

Abstract

MRI-guided transurethral ultrasound ablation (TULSA) is a new minimally-invasive modality for the treatment of prostate cancer, which aims to provide local disease control with low morbidity. A transurethral ultrasound device generates a continuous volume of thermal coagulation that is shaped precisely to the prostate using real-time MR thermometry and active temperature feedback control. The aim of this multi-center, prospective Phase I clinical study is to determine the safety and feasibility of MRI-guided TULSA, and to assess initial efficacy for treatment of localized prostate cancer.

Highlights

Background/introduction MRI-guided transurethral ultrasound ablation (TULSA) is a new minimally-invasive modality for the treatment of prostate cancer, which aims to provide local disease control with low morbidity
A transurethral ultrasound device generates a continuous volume of thermal coagulation that is shaped precisely to the prostate using realtime MR thermometry and active temperature feedback control
Treatment was completed under general anesthesia and drainage from a suprapubic catheter (SPC) which remains for 2 weeks

Summary

Introduction

MRI-guided transurethral ultrasound prostate ablation: midterm outcomes of a phase I clinical trial Background/introduction MRI-guided transurethral ultrasound ablation (TULSA) is a new minimally-invasive modality for the treatment of prostate cancer, which aims to provide local disease control with low morbidity. A transurethral ultrasound device generates a continuous volume of thermal coagulation that is shaped precisely to the prostate using realtime MR thermometry and active temperature feedback control.

Results

Conclusion